SCHEMBL1709898

SCHEMBL1709898

CC1(C)C(=O)Nc2cc(Nc3nc(N4CCC5(CCNC5)CC4)c4occc4n3)ccc21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 14/20 0.46
JAK2 O60674 4/20 0.42
LCK P06239 2/20 0.42
KDR P35968 2/20 0.42
BTK Q06187 2/20 0.42
AURKA O14965 1/20 0.42
ROCK2 O75116 1/20 0.42
STK16 O75716 1/20 0.42
ABL1 P00519 1/20 0.42
NTRK1 P04629 1/20 0.42
INSR P06213 1/20 0.42
FYN P06241 1/20 0.42
RET P07949 1/20 0.42
IGF1R P08069 1/20 0.42
PDGFRB P09619 1/20 0.42
SRC P12931 1/20 0.42
PDGFRA P16234 1/20 0.42
FLT1 P17948 1/20 0.42
MST1 P26927 1/20 0.42
LTK P29376 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1709843 0.95 SYK (0.45) SYKJAK2LCKKDRBTK
SCHEMBL3709849 0.88 SYK (0.56) SYKJAK2LCKKDRBTK
SCHEMBL3712019 0.85 SYK (0.47) SYKJAK2LCKKDRBTK
SCHEMBL3701522 0.85 SYK (0.44) SYKJAK2LCKKDRBTK
SCHEMBL3704914 0.84 SYK (0.54) SYKJAK2LCKKDRBTK
SCHEMBL3699447 0.84 SYK (0.47) SYKJAK2LCKKDRBTK
SCHEMBL3706098 0.84 SYK (0.57) SYKJAK2LCKKDRBTK
SCHEMBL3705361 0.83 SYK (0.54) SYKJAK2LCKKDRBTK
SCHEMBL3704548 0.83 SYK (0.45) SYKJAK2LCKKDRBTK
SCHEMBL3699830 0.83 SYK (0.43) SYKJAK2LCKKDRBTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8551981-B2 Furo[3,2-d]pyrimidine compounds ABBVIE INC. (US) 2013-10-08 US claimed
US-20120122846-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS ABBOTT LABORATORIES (US) 2012-05-17 US claimed
US-8551981-B2 Furo[3,2-d]pyrimidine compounds ABBVIE INC. (US) 2013-10-08 US disclosed
US-8551981-B2 Furo[3,2-d]pyrimidine compounds ABBVIE INC. (US) 2013-10-08 US disclosed
US-8551981-B2 Furo[3,2-d]pyrimidine compounds ABBVIE INC. (US) 2013-10-08 US disclosed
US-20120122846-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS ABBOTT LABORATORIES (US) 2012-05-17 US disclosed
US-20120122846-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS ABBOTT LABORATORIES (US) 2012-05-17 US disclosed
US-20120122846-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS ABBOTT LABORATORIES (US) 2012-05-17 US disclosed
WO-2012048222-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS ABBOTT LABORATORIES (US) 2012-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122846-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS CDK2, DPYD, CDK3 SYK 1176/4885JAK2 218/4885LCK 154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.